<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcblooddisord&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Blood Disorders - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcblooddisord/</link>
        <description>The latest research articles published by BMC Blood Disorders</description>
        <dc:date>2009-09-07T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/9/7" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/9/6" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/9/5" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/9/4" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/9/3" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/9/2" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/9/1" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/8/2" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/8/1" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2326/7/1" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/9/7">
        <title>Iron deficiency anemia is not a rare problem among women of reproductive ages in Ethiopia: a community based cross sectional study.</title>
        <description>Background:
In Ethiopia, the existence of iron deficiency anemia is controversial despite the fact that Ethiopia is one of the least developed in Africa with a high burden of nutrient deficiencies.
Methods:
The first large nutrition study of a representative sample of women in Ethiopia was conducted from June to July 2005 and a systematically selected sub-sample of 970 of these subjects, 15 to 49 years old, were used in this analysis of nutritional anemia. Hemoglobin was measured from capillary blood using a portable HemoCue photometer. For serum ferritin, venous blood from antecubital veins was measured by an automated Elecsys 1020 using commercial kits. Diets were assessed via simplified food frequency questionnaire. The association of anemia to demographic and health variables was tested by chi-square and a stepwise backward logistic regression model was applied to test the significant associations observed in chi square tests.
Results:
Mean hemoglobin &#177; SD was 11.5 &#177; 2.1 g/dL with a 29.4% prevalence of anemia. Mean serum ferritin was 58 &#177; 41.1 ug/L with a 32.1% prevalence of iron deficiency. The overall prevalence rate of iron deficiency anemia was 18.0%. Prevalence of anemia, iron deficiency, and iron deficiency anemia was highest among those 31-49 years old (p &lt; 0.05). Intake of vegetables less than once a day and meat less than once a week was common and was associated with increased anemia (p = 0.001). Although the prevalence of anemia was slightly higher among women with parasitic infestation the difference was not significant (p = 0.9). Nonetheless, anemia was significantly higher in women with history of illness and the association was retained even when the variable was adjusted for its confounding effect in the logistic regression models (AOR = 0.3; 95%CI = 0.17 to 0.5) signifying that the most probable causes of anemia is nutrition related and to some extent chronic illnesses.
Conclusion:
Moderate nutritional anemia in the form of iron deficiency anemia is a problem in Ethiopia and therefore, the need for improved supplementation to vulnerable groups is warranted to achieve the United Nation&apos;s Millennium Development Goals. Chronic illnesses are another important cause of anemia.</description>
        <link>http://www.biomedcentral.com/1471-2326/9/7</link>
                <dc:creator>Jemal Haidar</dc:creator>
                <dc:creator>Rebecca Pobocik</dc:creator>
                <dc:source>BMC Blood Disorders 2009, 9:7</dc:source>
        <dc:date>2009-09-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-9-7</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2009-09-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/9/6">
        <title>The role of religious leaders and faith organisations in haemoglobinopathies - a review</title>
        <description>Background:
Sickle cell disease (SCD) is now the most common genetic condition in the world including the UK with an estimate of over 12,500 affected people and over 300 new births per year. Blood transfusion therapy plays a very important role as a disease-modifying strategy in severe SCD e.g. primary and secondary stroke prevention and other acute life-threatening complications such as acute chest infections and acute multi-organ failure. Blood transfusion, however, carries a number of risks including alloimmunisation. There is the need to increase the level of awareness and education about SCD and also to increase blood donation drive among affected communities. These communities are mostly ethnic minority populations who are recognised to have poor access to health care services. Due to the strong impact of religion on these populations, faith organisations may provide potential access for health promotion and interventions.
Methods:
A literature search was conducted to find studies published between 1990&#8211;2008 aimed at examining the influence of religious leaders and faith organisations in health, with particular reference to haemoglobinopathies.
Results:
Eleven studies were reviewed covering a variety of health interventions. The findings suggest that involvement of religious leaders and faith organisations in health related interventions improved the level of acceptance, participation and positive health outcomes within the faith communities.
Conclusion:
Religious leaders and faith organisations have the potential to influence health education, health promotion and positive health outcomes amongst members of their faith community. They also provide potential access to at-risk populations for increasing awareness about SCD, encouraging health service utilization and ethnic blood donor drives.</description>
        <link>http://www.biomedcentral.com/1471-2326/9/6</link>
                <dc:creator>Thelma Toni-Uebari</dc:creator>
                <dc:creator>Baba Inusa</dc:creator>
                <dc:source>BMC Blood Disorders 2009, 9:6</dc:source>
        <dc:date>2009-08-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-9-6</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2009-08-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/9/5">
        <title>Profile of Hematological Abnormalities in Indian HIV infected Individuals</title>
        <description>Background:
Hematological abnormalities are a common complication of HIV infection. These abnormalities increase as the disease advances. Bone marrow abnormalities occur in all stages of HIV infection.
Methods:
Two hundred HIV infected individual were screened for hematological abnormalities from March 2007&#8211;March 2008. Absolute CD4 cell count analysis was carried out by flowcytometry. Depending on the results of the primary screening further investigations were performed, like iron studies, hemolytic work up, PNH work up and bone marrow evaluation. Other investigations included coagulation profile, urine analysis, blood culture (bacterial, fungal, mycobacterial), serology for Epstein Barr virus (EBV), Cytomegalovirus (CMV), Hepatitis B and C, and Parvo B19 infection.
Results:
The most common hematological abnormality was anemia, seen in 65.5% (131/200) patients. Iron deficiency anemia was seen in 49.2% (/200) cases while anemia of chronic disease occurred in 50.7% (/200) cases. Bone marrow evaluation was carried out in 14 patients out of which staging marrow was performed in 2 cases of non-Hodgkin&apos;s lymphoma (NHL) and did not show any bone marrow infiltration. In remaining12 cases bone marrow was done for evaluation of pancytopenia. Among patients with pancytopenia 50% (6/12) showed granulomas (4 were positive for AFB, 2 were positive for fungal cryptococci), 25% (3/12) showed hemophagocytosis. There was a strong negative correlation between anemia and CD4 counts in this study. Thrombocytopenia was seen in 7% (14/200) cases and had no significant correlation with CD4 counts. No patient had absolute neutrophil count (ANC) &lt; 800 cells/&#956;L. No case of coagulation abnormalities was found.
Conclusion:
Anemia in HIV patients can be a good clinical indicator to predict and access the underlying immune status. Patients should be investigated for hematological manifestations and appropriate steps should be taken to identify and treat the reversible factors.</description>
        <link>http://www.biomedcentral.com/1471-2326/9/5</link>
                <dc:creator>Byomakesh Dikshit</dc:creator>
                <dc:creator>Ajay Wanchu</dc:creator>
                <dc:creator>Ravinder Sachdeva</dc:creator>
                <dc:creator>Aman Sharma</dc:creator>
                <dc:creator>Reena Das</dc:creator>
                <dc:source>BMC Blood Disorders 2009, 9:5</dc:source>
        <dc:date>2009-08-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-9-5</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2009-08-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/9/4">
        <title>Application of tri-colour, dual fusion fluorescence in situ hybridization (FISH) system for the characterization of BCR-ABL1 fusion in chronic myelogenous leukaemia (CML) and residual disease monitoring</title>
        <description>Background:
We studied the application of the BCR-ABL1 + 9q34 tri-colour dual fusion fluorescence in situ hybridization (FISH) system in the characterization of fusion signal pattern and the monitoring of residual disease in chronic myelogenous leukaemia (CML). The signal constellation on metaphases with the tri-colour dual fusion system was defined. The knowledge of various signal patterns obtained from the different genetic rearrangements was further applied to the analysis of hybridization signals on interphase nuclei.
Methods:
BCR-ABL1 dual colour, dual fusion FISH (D-FISH) was performed on diagnostic samples of 22 CML patients. The tri-colour FISH system was performed on cases that showed aberrant signal patterns other than the classical 1 green (G) 1 orange (O) 2 fusions (F). Using the aqua band-pass filter, random signal overlap in interphase nuclei would be indicated by the presence of an aqua signal (ASS1), while genuine fusion was represented by the absence of the ASS1 signal.
Results:
Using the D-FISH system, the signal patterns could be categorized into 4 groups: group 1 (n = 17) showed the classical 1G1O2F; group 2 (n = 2) showed 2G1O1F indicating ABL1 deletion; group 3 (n = 1) showed 1G2O1F indicating BCR deletion; group 4 (n = 2) with 1G1O1F indicating reciprocal ABL1-BCR deletion. The tri-colour dual fusion system correlated with the D-FISH system for cases with der(9) deletion. The added aqua-labelled ASS1 probe was useful in differentiating random signal overlap from genuine BCR-ABL1 fusion in the interphase cells (group 4).
Conclusion:
Although the D-FISH probe was valuable in establishing the different patterns of aberrant signals and monitoring patients with the classic 2-fusion signals in CML, the tri-colour dual fusion probe should be used for patients with der(9) deletion to monitor response to treatment.</description>
        <link>http://www.biomedcentral.com/1471-2326/9/4</link>
                <dc:creator>Lisa Siu</dc:creator>
                <dc:creator>Edmond Ma</dc:creator>
                <dc:creator>Wai-shan Wong</dc:creator>
                <dc:creator>Man-hong Chan</dc:creator>
                <dc:creator>Kit-fai Wong</dc:creator>
                <dc:source>BMC Blood Disorders 2009, 9:4</dc:source>
        <dc:date>2009-07-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-9-4</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2009-07-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/9/3">
        <title>Prevalence, phenotype and inheritance of 
benign neutropenia in Arabs
</title>
        <description>Background:
Benign neutropenia, i.e., neutropenia not associated with an increased risk of infection, may result in serious medical consequences when a &apos;standard&apos; definition of neutropenia (absolute neutrophil count (ANC) &lt; 1.5 &#215; 109cells/L) is universally applied to all races. The aims of this study were to determine the prevalence of benign neutropenia among healthy Arabs and evaluate its mode of inheritance.
Methods:
ANCs were studied prospectively amongst a healthy indigenous population (n = 1032) from the United Arab Emirates undergoing a nation-wide sickle-cell and thalassemia screening program. The mean neutrophil count and the prevalence of benign neutropenia were compared by age, sex and amongst various tribes.
Results:
The mean neutrophil count (&#215; 109cells/L) was 3.3 (range 0.95&#8211;7.6). Benign neutropenia was present in 110 (10.7%) subjects of whom 24 (2.3%) individuals had moderate neutropenia (ANC 0.5 &#8211; 1.0 &#215; 109 cells/L). In the 22 tribe-family groups, the prevalence of benign neutropenia varied between 0% and 38%. Benign neutropenia showed no difference in the frequency amongst the sexes (p = 0.23) and it was independent of age (Spearman&apos;s rho = 0.05, p = 0.13). The age-related mean neutrophil count was the lowest in Arabs when compared with other ethnic groups (Blacks, Europeans and Mexicans). The inheritance of benign neutropenia was consistent with an autosomal dominant pattern; however, the diversity of observed phenotypes suggested the presence of more than one genetic variant for this trait.
Conclusion:
Arabs have a high prevalence of benign neutropenia that may be inherited as an autosomal dominant trait.</description>
        <link>http://www.biomedcentral.com/1471-2326/9/3</link>
                <dc:creator>Srdjan Denic</dc:creator>
                <dc:creator>Saad Showqi</dc:creator>
                <dc:creator>Christoph Klein</dc:creator>
                <dc:creator>Mohamed Takala</dc:creator>
                <dc:creator>Nicolas Nagelkerke</dc:creator>
                <dc:creator>Mukesh Agarwal</dc:creator>
                <dc:source>BMC Blood Disorders 2009, 9:3</dc:source>
        <dc:date>2009-03-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-9-3</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2009-03-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/9/2">
        <title>Factors associated with hospital readmission in sickle cell disease</title>
        <description>Background:
Sickle cell disease is the most frequent hereditary disease in Brazil, and people with the disease may be hospitalised several times in the course of their lives. The purpose of this study was to estimate the hazard ratios of factors associated with the time between hospital admissions.
Methods:
The study sample comprised all patients admitted, from 2000 to 2004, to a university hospital in Rio de Janeiro State, south-east Brazil, as a result of acute complications from sickle cell disease (SCD). Considering the statistical problem of studying individuals with multiple events over time, the following extensions of Cox&apos;s proportional hazard ratio model were compared: the independent increment marginal model (Andersen-Gill) and the random effects model.
Results:
The study considered 71 patients, who were admitted 223 times for acute events related to SCD. The hazard ratios for hospital readmission were statistically significant for the prior occurrence of vaso-occlusive crisis and development of renal failure. However, analysis of residuals of the marginal model revealed evidence of non-proportionality for some covariates.
Conclusion:
the results from applying the two models were generally similar, indicating that the findings are not highly sensitive to different approaches. The better fit by the frailty model suggests that there are unmeasured individual factors with impact on hospital readmission.</description>
        <link>http://www.biomedcentral.com/1471-2326/9/2</link>
                <dc:creator>Monique Loureiro</dc:creator>
                <dc:creator>Suely Rozenfeld</dc:creator>
                <dc:creator>Marilia Carvalho</dc:creator>
                <dc:creator>Rodrigo Portugal</dc:creator>
                <dc:source>BMC Blood Disorders 2009, 9:2</dc:source>
        <dc:date>2009-02-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-9-2</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2009-02-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/9/1">
        <title>FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia</title>
        <description>Background:
Primary eosinophlia associated with the FIP1L1-PDGFRA rearrangement represents a subset of chronic eosinophilic leukaemia (CEL) and affected patients are very sensitive to imatinib treatment. This study was undertaken in order to examine the prevalence and the associated clinicopathologic and genetic features of FIP1L1-PDGFRA rearrangement in a cohort of 15 adult patients presenting with profound eosinophilia (&gt; 1.5 &#215; 109/L).
Methods:
Reverse transcriptase-polymerase chain reaction (RT-PCR) was used for the detection of FIP1L1-PDGFRA rearrangement and the results confirmed by direct sequencing. C-KIT-D816V mutation was analysed retrospectively by PCR and restriction-fragment-length-polymorphism (PCR-RFLP), in all cases with primary eosinophilia.
Results:
Two male patients with splenomegaly carried the FIP1L1-PDGFRA rearrangement, whilst 2 others were ultimately classified as suffering from idiopathic hypereosinophlic syndrome (HES) and one from systemic mastocytosis. These patients were negative for the C-KIT-D816V mutation and received imatinib (100&#8211;400 mg daily). Patients with CEL and HES responded to imatinib and remained in complete haematological, clinical and molecular (for carriers of FIP1L1-PDGFRA rearrangement) remission for a median of 28.2 months (range: 11&#8211;54), whilst the patient with systemic mastocytosis did not respond. Interestingly, in both patients with FIP1L1-PDGFRA rearrangement, the breakpoints into PDGFRA were located within exon 12 and fused with exons 8 and 8a of FIP1L1, respectively.
Conclusion:
An early diagnosis of FIPIL1-PDGFRA-positive CEL and imatinib treatment offer to the affected patients an excellent clinical therapeutic result, avoiding undesirable morbidity. Moreover, although the molecular mechanisms underlying disease pathogenesis remain to be determined, imatinib can be effective in patients with idiopathic HES.</description>
        <link>http://www.biomedcentral.com/1471-2326/9/1</link>
                <dc:creator>Gedeon Loules</dc:creator>
                <dc:creator>Fani Kalala</dc:creator>
                <dc:creator>Nikolaos Giannakoulas</dc:creator>
                <dc:creator>Emmanouil Papadakis</dc:creator>
                <dc:creator>Panagiota Matsouka</dc:creator>
                <dc:creator>Matthaios Speletas</dc:creator>
                <dc:source>BMC Blood Disorders 2009, 9:1</dc:source>
        <dc:date>2009-02-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-9-1</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2009-02-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/8/2">
        <title>Estimation of transient increases in bleeding risk associated with physical activity in children with haemophilia</title>
        <description>Background:
Although it is widely appreciated that vigorous physical activity can increase the risk of bleeding episodes in children with haemophilia, the magnitude of the increase in risk is not known. Accurate risk estimates could inform decisions made by children with haemophilia and their parents about participation in physical activity and aid the development of optimal prophylactic schedules. The aim of this study is to provide an accurate estimate of the risks of bleeding associated with vigorous physical activity in children with haemophilia.Methods/DesignThe study will be a case-crossover study nested within a prospective cohort study. Children with moderate or severe haemophilia A or B, recruited from two paediatric haematology departments in Australia, will participate in the study. The child, or the child&apos;s parent or guardian, will report bleeding episodes experienced over a 12-month period. Following a bleeding episode, the participant will be interviewed by telephone about exposures to physical activity in the case period (8 hours before the bleed) and 2 control periods (an 8 hour period at the same time on the day preceding the bleed and an 8 hour period two days preceding the bleed). Conditional logistic regression will be used to estimate the risk of participating in vigorous physical activity from measures of exposure to physical activity in the case and control periods.DiscussionThis case-control study will provide estimates of the risk of participation in vigorous physical activity in children with haemophilia.</description>
        <link>http://www.biomedcentral.com/1471-2326/8/2</link>
                <dc:creator>Carolyn Broderick</dc:creator>
                <dc:creator>Robert Herbert</dc:creator>
                <dc:creator>Jane Latimer</dc:creator>
                <dc:creator>Chris Barnes</dc:creator>
                <dc:creator>Julie Curtin</dc:creator>
                <dc:creator>Paul Monagle</dc:creator>
                <dc:source>BMC Blood Disorders 2008, 8:2</dc:source>
        <dc:date>2008-06-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-8-2</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2008-06-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/8/1">
        <title>Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: a single blinded multi-centre randomized controlled clinical trial</title>
        <description>Background:
Influenza vaccines are recommended for administration by the intramuscular route. However, many physicians use the subcutaneous route for patients receiving an oral anticoagulant because this route is thought to induce fewer hemorrhagic side effects. Our aim is to assess the safety of intramuscular administration of influenza vaccine in patients on oral anticoagulation therapy.
Methods:
Design: Randomised, controlled, single blinded, multi-centre clinical trial. Setting: 4 primary care practices in Barcelona, Spain. Participants: 229 patients on oral anticoagulation therapy eligible for influenza vaccine during the 2003&#8211;2004 season. Interventions: intramuscular administration of influenza vaccine in the experimental group (129 patients) compared to subcutaneous administration in the control group (100 patients). Primary outcome: change in the circumference of the arm at the site of injection at 24 hours. Secondary outcomes: appearance of local reactions and pain at 24 hours and at 10 days; change in INR (International Normalized Ratio) at 24 hours and at 10 days. Analysis was by intention to treat using the 95% confidence intervals of the proportions or mean differences.
Results:
Baseline variables in the two groups were similar. No major side effects or major haemorrhage during the follow-up period were reported. No significant differences were observed in the primary outcome between the two groups. The appearance of local adverse reactions was more frequent in the subcutaneous administration group (37,4% vs. 17,4%, 95% confidence interval of the difference 8,2% to 31,8%).
Conclusion:
This study shows that the intramuscular administration route of influenza vaccine in patients on anticoagulant therapy does not have more side effects than the subcutaneous administration route.Registration numberNCT00137579 at clinicaltrials.gov</description>
        <link>http://www.biomedcentral.com/1471-2326/8/1</link>
                <dc:creator>Josep Casajuana</dc:creator>
                <dc:creator>Begona Iglesias</dc:creator>
                <dc:creator>Mireia Fabregas</dc:creator>
                <dc:creator>Francesc Fina</dc:creator>
                <dc:creator>Joan-Antoni Valles</dc:creator>
                <dc:creator>Rosa Aragones</dc:creator>
                <dc:creator>Mencia Benitez</dc:creator>
                <dc:creator>Edurne Zabaleta</dc:creator>
                <dc:source>BMC Blood Disorders 2008, 8:1</dc:source>
        <dc:date>2008-05-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-8-1</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2008-05-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2326/7/1">
        <title>Impact of delayed initiation of erythropoietin
in critically ill patients</title>
        <description>Background:
The purpose of this study was to evaluate the impact of recombinant human erythropoietin (rHuEPO) use for anemia of critical illness at a practice site where delayed initiation is common.
Methods:
Retrospective medical record review involving patients treated with rHuEPO for anemia of critical illness. Those patients given rHuEPO or diagnosed with end-stage renal disease (ESRD) prior to ICU admission were excluded. The primary endpoints were rHuEPO use and RBC transfusion patterns.
Results:
Complete data were collected for consecutive admissions of 126 patients. Average age (SD) and APACHE II score were 56.5 (18.6) years and 25 (7.8), respectively. The median ICU (IQR) and hospital length of stay (LOS) were 24 (11.25, 39) and 29 (17, 44.75) days, respectively. Treatment with rHuEPO was started an average of 12.5 +/- 10.5 days after ICU admission and given for 3.8 +/- 3.8 doses. Eighty percent of patients were transfused with an average total of 5.42 +/- 5.08 units received. RBC exposure inversely correlated with a lower mean hemoglobin response to rHuEPO. ICU LOS (p &lt; 0.0001), hemoglobin at 24 hours (p = 0.055), transfusion within 48 hours of admit (p &lt; 0.0001), and postoperative status (p = 0.019) were the best predictors of transfusion requirements (r2 = 0.37).
Conclusion:
Delayed initiation of rHuEPO for anemia of critical illness resulted in comparable hemoglobin and transfusion benefits. Future studies are needed to establish clinical benefit and role in therapy. RBC exposure may blunt the erythropoietic effects of rHuEPO, potentially frustrating benefits to those of greatest apparent need.</description>
        <link>http://www.biomedcentral.com/1471-2326/7/1</link>
                <dc:creator>Jeremiah Duby</dc:creator>
                <dc:creator>Brian Erstad</dc:creator>
                <dc:creator>Jacob Abarca</dc:creator>
                <dc:creator>James Camano</dc:creator>
                <dc:creator>Yvonne Huckleberry</dc:creator>
                <dc:creator>Stuart Bramblett</dc:creator>
                <dc:source>BMC Blood Disorders 2007, 7:1</dc:source>
        <dc:date>2007-10-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2326-7-1</dc:identifier>
        <prism:publicationName>BMC Blood Disorders</prism:publicationName>
        <prism:issn>1471-2326</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2007-10-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
